Simultaneous determination of SU5416 and its phase I and phase II metabolites in rat and dog plasma by LC/MS/MS

SU5416, Z-3-[(2,4-dimethylpyrrol-5-yl)methylidenyl]-2-indolinone, is a cytostatic substance in development as an anti-angiogenic agent. SU5416 has several phase I and phase II metabolites including SU9838, SU6595, SU6689, 5'-hydroxy glucuronide of SU5416 and 5'-acyl glucuronide of SU5416....

Full description

Saved in:
Bibliographic Details
Published in:Journal of pharmaceutical and biomedical analysis 2001-07, Vol.25 (5-6), p.821-832
Main Authors: YEPING ZHAO, YANG, Cheng Y, HAZNEDAR, Joshua, ANTONIAN, Lida
Format: Article
Language:English
Subjects:
Analysis
Angiogenesis Inhibitors - blood
Angiogenesis Inhibitors - pharmacokinetics
Animals
Biological and medical sciences
Chromatography, Liquid - methods
Dogs
General pharmacology
Indoles - blood
Indoles - pharmacokinetics
Mass Spectrometry - methods
Medical sciences
Pharmacology. Drug treatments
Pyrroles - blood
Pyrroles - pharmacokinetics
Rats
Reproducibility of Results
Sensitivity and Specificity
SU5416
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:SU5416, Z-3-[(2,4-dimethylpyrrol-5-yl)methylidenyl]-2-indolinone, is a cytostatic substance in development as an anti-angiogenic agent. SU5416 has several phase I and phase II metabolites including SU9838, SU6595, SU6689, 5'-hydroxy glucuronide of SU5416 and 5'-acyl glucuronide of SU5416. In order to support the preclinical studies, a liquid chromatography/mass spectrometry/mass spectrometry (LC/MS/MS) method for simultaneous determination of SU5416 and its metabolites in rat and dog plasma was developed. This method is fast, simple, sensitive (LOQ=2.0 ng/ml), reproducible and has a wide linear range (2.0-5000 ng/ml for SU5416, 2.0-2000 ng/ml for SU6689 and 2.0-1000 ng/ml for SU9838 and SU6595). This method was applied to rat and dog plasma samples obtained from pharmacokinetic and toxicokinetic studies.
ISSN:0731-7085
1873-264X
DOI:10.1016/S0731-7085(01)00341-7